Medivir AB's Simeprevir Is Now Available For Hepatitis C Patients In Japan, USA And Canada

Published: Dec 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden—Medivir AB (OMX: MVIR) Based on the recent approvals in Japan, Canada and USA, simeprevir is now available in all three markets. Simeprevir is administered once-daily for 12 weeks in combination with pegylated interferon and ribavirin, followed by pegylated interferon and ribavirin alone for an additional 12 or 36 weeks.

Help employers find you! Check out all the jobs and post your resume.

Back to news